Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anrikefon vs Nalfurafine for Sleep Quality in Hemodialysis Patients with CKD-associated Pruritus
ChiCTR2600117947Phase 4Not yet recruiting
- Sponsor
- Southern Medical University Zhujiang Hospital
- Start
- Jan 2026
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in chronic kidney disease (CKD) comparing Anrikefon injection arm with Oral Nalfurafine arm (2 arms). Primary endpoint: Pittsburgh Sleep Quality Index. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
hsk21542nalfurafine
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on ChiCTR2600117947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117947.